1 |
Ghanem N, Uhl M, Brink I, Schafer O, Kelly T, Moser E, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol 2005;55:41-55
DOI
ScienceOn
|
2 |
Nakamoto Y, Osman M, Wahl RL. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Clin Nucl Med 2003;28:302-7
DOI
|
3 |
Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998;16:3375-9
DOI
|
4 |
O'Sullivan JM, Cook GJR. A review of the efficacy of bone scanning in prostate and breast cancer. Q J Nucl Med 2002; 46:152-9
|
5 |
Peterson JJ, Kransdorf MJ, O'Connor MI. Diagnosis of occult bone metastases: positron emission tomography. Clin Orthop Relat Res 2003;415s:s120-8
DOI
|
6 |
Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetinm-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002;128:325-8
DOI
|
7 |
Shreve PD, Grossman HB, Gross MD, Warl RL. Metastatic prostate cancer: initial finding of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996;199:751-6
DOI
|